Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Dexamethasone Induction for AL Amyloidosis
NCT01083316Phase 2Completed
- Sponsor
- Boston Medical Center
- Start
- Sep 2009
- Primary completion
- Aug 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in amyloid light chain amyloidosis, sponsored by Boston Medical Center. Primary endpoints: Number of Participants With Disease Response at 1 year, Number of Participants Surviving at 100 Days Post Transplant and 1 more. Started Sep 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT01083316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083316.